Tumor Treating Fields Showing Early Success for Mesothelioma

Dr. Giovanni Ceresoli doesn’t think Tumor Treating Fields will work for every patient with mesothelioma cancer, but he knows it will work for some. They are in his clinic. As the principal investigator of the multicenter clinical trial that led to approval by the U.S. Food and Drug Administration in May, Ceresoli has played a major role in the development of this latest mesothelioma treatment. “It might be too early to say this is a major breakthrough — we need more data — but I hope it is. I know it’s something promising, very promising,” Cerosoli told The Mesothelioma Center at Asbestos.com. “I can say that based on what we’ve seen.” Tumor Treating Fields, which works in synergy with chemotherapy, is designed to disrupt cancer cell division through electric fields tuned to specific frequencies. Cerosoli is section manager in the Department of Oncology at Cliniche Humanitas Gavazzeni in Bergamo, Italy, one of 12 sites across Europe that conducted the study called STELLAR. The phase II trial involved using the combination of chemotherapy and the NovoTTF-100L System. The device is manufactured by Novocure, a global oncology company based in the United Kingdom with operations in Australia, the United States, Japan and Switzerland. Study results were released in 2018 and included one- and two-year survival rates of 62.2% and 41.9%, respectively. The FDA approved it for first-line treatment under its Humanitarian Device Exemption earlier this year. ...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news